ArticleJournal of translational medicine2026
Circulating alpha-1 antitrypsin and its c-terminal peptides differentiate bacterial from viral community-acquired pneumonia.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDistinguishing bacterial from viral community-acquired pneumonia (CAP) remains a major clinical challenge, often leading to inappropriate antimicrobial use. Alpha-1 antitrypsin (AAT) is an acute-phase protein that regulates neutrophil protease activity and is cleaved during inflammation, generating bioactive peptides. We investigated whether circulating AAT and its peptides could discriminate bacterial from viral CAP.
methodsSerum samples were obtained from 81 prospectively enrolled adults with CAP (bacterial, n = 36; viral, n = 45) at hospital admission (day 0) and day 3. AAT concentrations were measured by ELISA, and nine AAT-derived C-terminal peptides were quantified by LC-MS/MS. Associations with CAP etiology were assessed using multivariable logistic regression and receiver operating characteristic (ROC) analyses.
resultsAAT concentrations were significantly higher in bacterial than viral CAP at both admission (p = 0.006) and day 3 (p < 0.001) and remained independently associated with bacterial etiology after adjustment for clinical covariates, whereas C-reactive protein (CRP) did not. A predictive model combining AAT, age, and leukocyte count demonstrated the highest discriminatory performance (AUC = 0.803). Four of nine analyzed peptides (C36, C37, C40, and C42) were consistently detectable. C37 levels were higher in bacterial CAP at admission (p = 0.010). C36 showed a similar trend but declined from day 0 to day 3 (p = 0.006). In contrast, C40 levels increased in viral CAP (p = 0.017), resulting in a higher C40/AAT ratio at admission compared with bacterial CAP (p = 0.014). Correlations between AAT, peptides, and inflammatory markers were observed in bacterial but not in viral CAP, indicating distinct patterns of AAT processing.
conclusionsCirculating AAT independently discriminates bacterial from viral CAP and, when combined with age and leukocyte count, show improved discriminatory performance compared with CRP-based models. Distinct patterns of AAT-derived peptides suggest etiology-specific proteolytic processing and merit further evaluation as markers for differentiating bacterial and viral CAP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.